Walleye Trading’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.47M | Buy |
8,500
+5,900
| +227% | +$1.09M | ﹤0.01% | 1893 |
|
|
2025
Q4 | $519K | Sell |
2,600
-1,800
| -41% | -$327K | ﹤0.01% | 2803 |
|
|
2025
Q3 | $688K | Buy |
4,400
+3,100
| +238% | +$492K | ﹤0.01% | 2519 |
|
|
2025
Q2 | $197K | Sell |
1,300
-6,400
| -83% | -$853K | ﹤0.01% | 3248 |
|
|
2025
Q1 | $1.16M | Buy |
7,700
+1,500
| +24% | +$251K | ﹤0.01% | 1970 |
|
|
2024
Q4 | $1.14M | Buy |
6,200
+3,100
| +100% | +$597K | ﹤0.01% | 2071 |
|
|
2024
Q3 | $611K | Buy |
3,100
+1,600
| +107% | +$333K | ﹤0.01% | 2397 |
|
|
2024
Q2 | $310K | Sell |
1,500
-2,000
| -57% | -$453K | ﹤0.01% | 2822 |
|
|
2024
Q1 | $948K | Sell |
3,500
-7,200
| -67% | -$1.72M | ﹤0.01% | 2299 |
|
|
2023
Q4 | $2.53M | Sell |
10,700
-3,000
| -22% | -$590K | 0.01% | 1743 |
|
|
2023
Q3 | $2.68M | Sell |
13,700
-1,800
| -12% | -$370K | 0.01% | 1558 |
|
|
2023
Q2 | $3.26M | Buy |
15,500
+5,100
| +49% | +$1.01M | 0.01% | 1286 |
|
|
2023
Q1 | $2.1M | Buy |
10,400
+5,500
| +112% | +$1.25M | ﹤0.01% | 1639 |
|
|
2022
Q4 | $1.07M | Buy |
4,900
+2,900
| +145% | +$633K | ﹤0.01% | 2168 |
|
|
2022
Q3 | $394K | Sell |
2,000
-12,500
| -86% | -$2.7M | ﹤0.01% | 3115 |
|
|
2022
Q2 | $3.1M | Buy |
+14,500
| New | +$3.54M | 0.01% | 1333 |
|
|
2022
Q1 | – | Sell |
-800
| Closed | -$301K | – | 5405 |
|
|
2021
Q4 | $301K | Buy |
800
+200
| +33% | +$77.7K | ﹤0.01% | 3474 |
|
|
2021
Q3 | $248K | Buy |
+600
| New | +$249K | ﹤0.01% | 3648 |
|
|
2021
Q2 | – | Sell |
-5,100
| Closed | -$1.48M | – | 5203 |
|
|
2021
Q1 | $1.48M | Sell |
5,100
-4,100
| -45% | -$1.14M | 0.01% | 1595 |
|
|
2020
Q4 | $2.3M | Buy |
9,200
+5,100
| +124% | +$1.21M | 0.01% | 1276 |
|
|
2020
Q3 | $928K | Buy |
4,100
+1,700
| +71% | +$353K | 0.01% | 1712 |
|
|
2020
Q2 | $418K | Sell |
2,400
-200
| -8% | -$31.9K | ﹤0.01% | 2412 |
|
|
2020
Q1 | $328K | Buy |
2,600
+1,900
| +271% | +$285K | ﹤0.01% | 2214 |
|
|
2019
Q4 | $107K | Sell |
700
-8,300
| -92% | -$1.15M | ﹤0.01% | 3526 |
|
|
2019
Q3 | $1.19M | Sell |
9,000
-1,700
| -16% | -$228K | 0.01% | 1464 |
|
|
2019
Q2 | $1.52M | Sell |
10,700
-2,300
| -18% | -$312K | 0.01% | 1260 |
|
|
2019
Q1 | $1.89M | Sell |
13,000
-12,700
| -49% | -$1.67M | 0.01% | 1124 |
|
|
2018
Q4 | $2.91M | Buy |
25,700
+5,600
| +28% | +$701K | 0.02% | 788 |
|
|
2018
Q3 | $2.7M | Buy |
+20,100
| New | +$2.48M | 0.01% | 1059 |
|
Other funds holding CRL
VCM
VPM
Walleye Trading's CRL Position: Q1 2026 in Review
Walleye Trading increased its Charles River Laboratories (CRL) stake by 3,286% in Q1 2026, buying an estimated $5.7M and bringing the position to 31,661 shares worth $5.46M. The position accounts for 0.01% of the portfolio, ranked #1099.
Walleye Trading first reported a position in CRL in Q3 2014 and has held it in 19 quarters since. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.
- Walleye Trading held 31,661 shares of Charles River Laboratories worth $5.46M as of Q1 2026.
- Walleye Trading bought 30,726 Charles River Laboratories shares in Q1 2026, an estimated $5.7M.
- Charles River Laboratories made up 0.01% of Walleye Trading's portfolio in Q1 2026, its #1099 holding.
- Walleye Trading first reported a position in Charles River Laboratories in Q3 2014 and has held it in 19 quarters since.
- 557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.
Based on Walleye Trading's 13F filing for Q1 2026, filed 11 May 2026.